Ceforanide

Ceforanide
Names
	IUPAC name (6R,7R)-7-{[2-[2-(aminomethyl)phenyl]acetyl]amino}-3-; {[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl}-8-oxo-; 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid;
Clinical data
WHO AWaRe
Routes of; use	Intramuscular
External links
AHFS/Drugs.com	International Drug Names
Pharmacokinetics
Protein binding	80.6%
Metabolism	Nil
Elimination half-life	2.6 to 2.98 hours
Excretion	Kidney
Chemical and physical data
Formula	C20H21N7O6S2
Molar mass	519.55 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3ccccc3CN)CSc4nnnn4CC(=O)O)C(=O)O;
	InChI InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1 ; Key:SLAYUXIURFNXPG-CRAIPNDOSA-N ;

Ceforanide is an antibiotic.^[1]

It is in the second-generation cephalosporin family of medications.^[1]

References

↑ ^1.0 ^1.1 Beauduy, Camille E.; Winston, Lisa G. (2020). "43. Beta-lactam and other cell wall - & membrane - active antibiotics". In Katzung, Bertram G.; Trevor, Anthony J. (eds.). Basic and Clinical Pharmacology (15th ed.). New York: McGraw-Hill. p. 833. ISBN 978-1-260-45231-0. Archived from the original on 2021-10-10. Retrieved 2021-11-30.

Crowle A, Sbarbaro J, May M (1988). "Effects of isoniazid and of ceforanide against virulent tubercle bacilli in cultured human macrophages". Tubercle. 69 (1): 15–25. doi:10.1016/0041-3879(88)90036-0. PMID 3140456.
Campoli-Richards D, Lackner T, Monk J (1987). "Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy". Drugs. 34 (4): 411–37. doi:10.2165/00003495-198734040-00001. PMID 3315624.
Cone L, Barton S, Woodard D (1987). "Treatment of scleroma with ceforanide". Arch Otolaryngol Head Neck Surg. 113 (4): 374–6. doi:10.1001/archotol.1987.01860040036012. PMID 3814386.

This systemic antibiotic-related article is a stub. You can help MDWiki by expanding it.

Names

IUPAC name (6R,7R)-7-{[2-[2-(aminomethyl)phenyl]acetyl]amino}-3- {[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl}-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
Clinical data
WHO AWaRe
Routes of use	Intramuscular
External links
AHFS/Drugs.com	International Drug Names
Pharmacokinetics
Protein binding	80.6%
Metabolism	Nil
Elimination half-life	2.6 to 2.98 hours
Excretion	Kidney
Chemical and physical data
Formula	C₂₀H₂₁N₇O₆S₂
Molar mass	519.55 g·mol⁻¹
3D model (JSmol)	Interactive image
SMILES O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3ccccc3CN)CSc4nnnn4CC(=O)O)C(=O)O
InChI InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1^Y Key:SLAYUXIURFNXPG-CRAIPNDOSA-N^Y